Awakn Life Sciences Announces the Findings from the Phase II A/B Study Are to Be Published in the American Journal of… Nov 4, 2021
BevCanna Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program Nov 3, 2021
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder Nov 3, 2021
